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Background
Several monoclonal antibodies (MAbs) with demonstrated
clinical anti-cancer activities have been engineered as fully
human IgG1 entities to also encompass their potential to
mediate antibody-dependent cell-mediated cytotoxicity
(ADCC) of human tumor cells. Avelumab (MSB0010718C,
EMD Serono, Pfizer) is a fully human IgG1 MAb targeting
the co-regulatory protein Programmed Death-Ligand 1
(PD-L1), and is thus distinct from other MAbs targeting
the PD-L1/PD-1 axis currently being evaluated in clinical
trials. Concern has been raised that an anti-PD-L1 anti-
body capable of inducing ADCC may negatively affect PD-
L1 expressing immune cell subtypes. This work is intended
to determine if there is any validity to this concern.
Methods
The clinical activity of Avelumab, observed in several
tumor types in ongoing clinical studies such as
NCT01772004, has been and will be reported elsewhere.
In the studies reported here, Avelumab is shown to med-
iate ADCC of several types of human tumor cell lines (e.g.,
breast, lung, bladder carcinomas) in vitro, with tumor cell
lysis mediated mainly by human CD16+ monocytes and
natural killer (NK) cells. Since some human immune cell
subsets express PD-L1 on their surface, studies were
undertaken to evaluate changes in the frequency of
immune cell subsets in peripheral blood mononuclear
cells (PBMC) from cancer patients pre- vs post-treatment
with Avelumab. Immune cells evaluated were PD-L1 posi-
tive and PD-L1 negative subsets of the following: CD4+
T cells, CD8+ T cells, NK cells, regulatory T cells (Tregs),
myeloid-derived suppressor cells (MDSC), natural killer
T cells (NKT), plasmacytoid dendritic cells (DC), conven-
tional DC, and B cells.
Results
Forty-two post-treatment PBMC samples were evaluated
as follows: pre vs 1 dose of Avelumab (day 15, n = 19); pre
vs 3 doses of Avelumab (day 43, n = 14); and pre vs 9
doses of Avelumab (day 127, n = 16). In all cases there
were no statistical differences pre- vs post-treatment in
any immune cell subset, and at any time point analyzed,
regardless of whether the immune subset expressed
PD-L1 or not. In addition, no changes were observed in
absolute lymphocyte counts at any time point analyzed.
Statistical analysis of all relevant immune cell subsets will
be presented.
Conclusion
While immune cell subsets pre- vs post-treatment
continue to be analyzed in various patient cohorts, these
studies provide evidence that Avelumab, a fully human
IgG1 MAb, capable of mediating ADCC, can be adminis-
tered safely to cancer patients without altering the balance
of numerous PBMC immune cell subsets.
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